Summaries for Patients |

The Effect of Estrogen Plus Progestin on Coronary Heart Disease FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full report titled “Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear? A Randomized Trial.” It is in the 16 February 2010 issue of Annals of Internal Medicine (volume 152, pages 211-217). The authors are S. Toh, S. Hernández-Díaz, R. Logan, J.E. Rossouw, and M.A. Hernán.

Ann Intern Med. 2010;152(4):I-40. doi:10.7326/0003-4819-152-4-201002160-00002
Text Size: A A A

What is the problem and what is known about it so far?

Women who receive hormone therapy after menopause have an increased risk for heart attacks and other problems related to the arteries in their hearts. Some persons, however, believe that there may not be an increased risk when women start hormone therapy soon after menopause.

Why did the researchers do this particular study?

One study of a large number of nurse-participants who decided whether to take or not take hormone therapy after menopause found a possible increased risk in the first 3 years of use in women who started hormone therapy within 10 years after menopause, but this study could not rule out the possibility that something other than hormone therapy caused the increased risk.

Who was studied?

16 608 postmenopausal women aged 50 to 79 years who had an intact uterus when the study started.

How was the study done?

Women were randomly assigned to receive either combined hormone therapy (estrogen plus progestin) or a placebo.

What did the researchers find?

A possible increased risk was present in the first 2 years in women who started hormone therapy within 10 years after menopause, and increased risk persisted until about 6 years after use.

What were the limitations of the study?

The results could have occurred by chance, but this information is, and will probably be for a long time, the best available evidence on this topic.

What are the implications of the study?

Most women use combined hormone therapy to treat the symptoms of menopause, which means they start hormone therapy soon after menopause and generally use it for less than 6 years. These women should not expect hormone therapy to protect them from heart attacks, and they may need to worry about a possible slightly increased risk for heart attacks.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.